Taylor Frigon Capital Management LLC reduced its position in Compugen Ltd. (NASDAQ:CGEN) by 3.7% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 721,505 shares of the biotechnology company’s stock after selling 27,788 shares during the period. Compugen accounts for 3.0% of Taylor Frigon Capital Management LLC’s investment portfolio, making the stock its largest holding. Taylor Frigon Capital Management LLC’s holdings in Compugen were worth $4,300,000 at the end of the most recent reporting period.
Several other large investors have also recently bought and sold shares of CGEN. Nikko Asset Management Americas Inc. lifted its position in shares of Compugen by 379.7% in the third quarter. Nikko Asset Management Americas Inc. now owns 7,824,454 shares of the biotechnology company’s stock worth $33,097,000 after buying an additional 6,193,417 shares in the last quarter. Renaissance Technologies LLC increased its stake in Compugen by 20.7% during the second quarter. Renaissance Technologies LLC now owns 557,800 shares of the biotechnology company’s stock worth $2,142,000 after acquiring an additional 95,500 shares during the last quarter. Phoenix Holdings Ltd. bought a new stake in Compugen during the third quarter worth approximately $225,000. Royal Bank of Canada increased its stake in Compugen by 115.4% during the second quarter. Royal Bank of Canada now owns 57,500 shares of the biotechnology company’s stock worth $221,000 after acquiring an additional 30,800 shares during the last quarter. Finally, State Street Corp bought a new stake in Compugen during the third quarter worth approximately $92,000. Institutional investors own 42.20% of the company’s stock.
Several equities research analysts have weighed in on CGEN shares. Cantor Fitzgerald started coverage on Compugen in a research note on Wednesday, January 15th. They set an “overweight” rating and a $10.00 price objective on the stock. Zacks Investment Research cut Compugen from a “buy” rating to a “hold” rating in a research note on Monday, January 13th. BidaskClub raised Compugen from a “buy” rating to a “strong-buy” rating in a research note on Sunday, November 3rd. Finally, ValuEngine cut Compugen from a “hold” rating to a “sell” rating in a research note on Friday, January 3rd. One research analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $8.42.
NASDAQ CGEN traded down $0.07 during trading hours on Friday, hitting $6.52. 22,657 shares of the company were exchanged, compared to its average volume of 273,735. The stock has a 50-day moving average price of $5.89 and a 200 day moving average price of $4.66. The company has a quick ratio of 7.19, a current ratio of 7.19 and a debt-to-equity ratio of 0.07. Compugen Ltd. has a 52 week low of $2.73 and a 52 week high of $6.57. The stock has a market cap of $318.02 million, a PE ratio of -13.04 and a beta of 2.74.
Compugen (NASDAQ:CGEN) last issued its quarterly earnings data on Monday, November 11th. The biotechnology company reported ($0.10) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.11) by $0.01. As a group, sell-side analysts anticipate that Compugen Ltd. will post -0.44 earnings per share for the current year.
Compugen Company Profile
Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations.
Featured Article: Most Active Stocks: Dollar Volume vs Share Volume
Want to see what other hedge funds are holding CGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Compugen Ltd. (NASDAQ:CGEN).
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.